MilliporeSigma Announces Neoclease as Winner of 2025 North American Advance Biotech Grant

BURLINGTON, Mass.--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced Neoclease as the winner of the 2025 North American Advance Biotech Grant. The Boston-based biotech startup develops AI-designed gene editing therapies for Parkinson’s disease. “We’re committed to empowering biotech innovators who are advancing transformative modalities like gene editing,” said Sebastián Arana,